Law360, New York (January 10, 2006, 12:00 AM ET) -- Cephalon Inc. has settled a patent dispute with a fourth potential competitor, part of its ongoing efforts to delay generic production of the narcolepsy drug Provigil.
The pharmaceutical company granted Mylan Pharmaceuticals Inc., a key player in the generic pharmaceutical industry, a nonexclusive agreement to launch a generic version of the drug in 2011. The agreement overrides plans by the drug maker to launch the drug before the expiration of Cephalon’s patent that year.
Mylan will pay Cephalon royalties generated from the sales.
Under the agreement,...
Cephalon, Mylan Settle Patent Dispute Over Provigil
To view the full article, take a free trial now.
